Merck’s plan to buy Lexington’s Cubist Pharmaceuticals Inc. for $9.5 billion is just the latest example of Big Pharma expanding its presence in Greater Boston. Pfizer, Novartis, Sanofi, Takeda, and Shire are among those that have grabbed a stake in the local market.
This paper discusses the major trends in the pharmaceutical and biotechnology industries, and the resultant considerations for senior executives. It looks at how companies are seeking inorganic growth through mergers and acquisition.
Erin Smith's insight:
The shake-up continues, with huge opportunities for new entrants and new thinking... great times! (for some)
The state of big data in 2014 (chart) VentureBeat Gradually, the use of big data is spreading to more industries, such as healthcare and biotech (particularly in genomics) or education. This is only the beginning.
The cost of making a new drug has grown to nearly $2.6B, according to the latest and greatest from Tufts Center for the Study of Drug Development (here). That’s a big and almost unfathomable number. Critics immediately pounced on it, calling anyone who believed it a flatlander (here), and suggesting [...]
With the recent announcement of the launch of Indie Bio (our new idea stage biotech accelerator launching in downtown San Francisco this Jan and in Cork in the summer) and the addition of the Berkeley Biolabs team, we thought it was time to send out a request for startups, not just any startups, idea stage …
The Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) have ramped up their prosecution of corporations and officers for violations of the Foreign Corrupt Practices Act (FCPA).
Erin Smith's insight:
An interesting discussion on the "antibribery" position facing Pharmas in the US (there are similar laws in the UK). Of course this does not affect just Pharmas, or just companies based in the US, and biotech and device companies who deal with Pharmas need to adopt compliance measures to ensure they don't get caught up in any misdeeds of their Pharma partners.
VentureBeat Dr. McCoy would be proud: XPrize announces finalists in health 'Tricorder ... VentureBeat MESI Simplifying diagnostics (Ljubljana, Slovenia), a team from diagnostic medical device manufacturer MESI and led by company CEO, Jakob Susteric.
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.